LABSTANDARD BIOTOOLS INC.

Nasdaq fluidigm.com


$ 2.01 $ -0.09 (-4.31 %)    

Tuesday, 17-Sep-2024 15:59:55 EDT
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 2
$ 2.00 x 1,448
-- x --
-- - --
$ 1.21 - $ 3.05
1,385,705
na
742.31M
$ 2.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-01-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-08-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-03-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 02-26-2015 12-31-2014 10-K
40 11-06-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-standard-biotools-lowers-price-target-to-275

TD Cowen analyst Daniel Brennan maintains Standard BioTools (NASDAQ:LAB) with a Buy and lowers the price target from $3.5 to...

 standard-biotools-says-cfo-jeffrey-black-will-resign-from-company-effective-august-31-2024

Alex Kim, the Company's Chief Operating Officer and co-founder of Standard BioTools, will serve as Standard BioTools' i...

 standard-biotools-q2-2024-gaap-eps-012-misses-010-estimate-sales-37205m-miss-48250m-estimate

Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(...

 standard-biotools-filed-for-offering-of-up-to-1051m-common-shares-by-the-selling-securityholders

-S-3 https://www.sec.gov/Archives/edgar/data/1162194/000110465924072927/tm2417094-1_s3.htm

 standard-biotools-reaffirms-fy24-revenue-guidance-of-200m-205m

  Outlook for 2024 For fiscal year 2024, the Company reaffirmed full year revenue guidance, which is expected to be in the ra...

 standard-biotools-q1-2024-gaap-eps-027-misses-012-estimate-sales-45540m-miss-46006m-estimate

Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(...

 standard-biotools-plans-operational-restructuring--implements-reduction-of-approximately-10-of-its-total-workforce

The restructuring plan is expected to generate annualized operating expense savings of $45 million to $50 million in fiscal 202...

 td-cowen-initiates-coverage-on-standard-biotools-with-buy-rating-announces-price-target-of-35

TD Cowen analyst Daniel Brennan initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION